| ［1］ |
Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult⁃onset autoinflammatory disease［J］. N Engl J Med, 2020,383（27）:2628⁃2638. doi: 10.1056/NEJMoa 2026834.
|
| ［2］ |
Grayson PC, Patel BA, Young NS. VEXAS syndrome［J］. Blood, 2021,137（26）:3591⁃3594. doi: 10.1182/blood.2021011455.
|
| ［3］ |
Diarra A, Duployez N, Terriou L. Mutant UBA1 and severe adult⁃onset autoinflammatory disease［J］. N Engl J Med, 2021,384（22）:2163⁃2164. doi: 10.1056/NEJMc2102124.
|
| ［4］ |
Georgin⁃Lavialle S, Terrier B, Guedon AF, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large⁃scale analysis of a multicentre case series of 116 French patients［J］. Br J Dermatol, 2022,186（3）:564⁃574. doi: 10.1111/bjd.20805.
|
| ［5］ |
Sterling D, Duncan ME, Philippidou M, et al. VEXAS syndrome （vacuoles, E1 enzyme, X⁃linked, autoinflammatory, somatic） for the dermatologist［J］. J Am Acad Dermatol, 2023,89（6）:1209⁃1214. doi: 10.1016/j.jaad.2022.01.042.
|
| ［6］ |
Zakine E, Schell B, Battistella M, et al. UBA1 variations in neutrophilic dermatosis skin lesions of patients with VEXAS syndrome［J］. JAMA Dermatol, 2021,157（11）:1349⁃1354. doi: 10.1001/jamadermatol.2021.3344.
|
| ［7］ |
Alegría⁃Landa V, Rodríguez⁃Pinilla SM, Santos⁃Briz A, et al. Clinicopathologic, immunohistochemical, and molecular features of histiocytoid sweet syndrome［J］. JAMA Dermatol, 2017,153（7）:651⁃659. doi: 10.1001/jamadermatol.2016.6092.
|
| ［8］ |
Ferrada MA, Savic S, Cardona DO, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis［J］. Blood, 2022,140（13）:1496⁃1506. doi: 10.1182/blood.2022 016985.
|
